FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W56677962> ?p ?o ?g. }

• W56677962 endingPage "63" @default.
• W56677962 startingPage "37" @default.
• W56677962 abstract "Renzapride (ATL-1251), a novel benzamide, is currently under clinical development for the treatment of irritable bowel syndrome (IBS). Previous in vitro and in vivo experimental studies have characterized renzapride as a full serotonin 5-HT(4) receptor agonist on the gut and a 5-HT(3) receptor antagonist. Clinical studies have confirmed the therapeutic efficacy, tolerability and safety of renzapride in patients with constipation-predominant IBS. This study set out to characterize the pharmacological profile of renzapride and its potential metabolic products at both 5-HT and other monoamine receptors in the gut.The affinity of renzapride, its (+) and (-) enantiomers, and its primary metabolite, renzapride N-oxide and its enantiomers, for serotonin receptors was assessed by means of in vitro radioligand binding inhibition studies. After membranes prepared from animal tissue or membranes of cell lines transfected with cloned human receptors had been incubated with radiolabelled ligand with high affinity for a specific receptor, renzapride was added to competitively inhibit this binding. Levels of bound radioligand were measured by filtration and counting of the bound radioactivity. In instances where >50% inhibition of radioligand binding had occurred, the inhibition constant (K(i)) was calculated. Metabolism of renzapride by liver microsomes was assessed by incubating 10 micromol/L renzapride with human liver microsome samples for 60 minutes at 37 degrees C. After the reaction was stopped, the samples were centrifuged and the supernatant analysed for metabolites by high-pressure liquid chromatography (HPLC). The potential inhibitory effects of renzapride on cytochrome P450 (CYP) enzymes were assessed by incubating renzapride at various concentrations over a 1-500 micromol/L concentration range with microsomes genetically engineered to express a single CYP.Renzapride was selective for serotonergic receptors and, in particular, had high affinity for human 5-HT(3) and guinea-pig 5-HT(4) receptors (K(i) 17 and 477 nm, respectively). Inhibitory properties at 5-HT(2B) receptors were also identified for renzapride, as well as some affinity for 5-HT(2A) and 5-HT(2C) receptors. Renzapride N-oxide and its enantiomers demonstrated much lower affinity for all 5-HT receptors compared with renzapride. Renzapride was metabolized by liver microsomes to a limited extent and there was no significant non-microsomal metabolism of renzapride. Renzapride did not inhibit the major CYP drug-metabolizing enzymes CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2E1 or CYP3A4 at concentrations consistent with use in a clinical setting.These results confirm and extend earlier studies in animal and human receptors that show renzapride is a potent and generally full 5-HT(4) receptor agonist and 5-HT(3) receptor antagonist. The results reported in the present study indicate that the metabolites of renzapride are minor and are unlikely to contribute to its therapeutic profile or lead to interaction of renzapride with other drugs that inhibit the major drug-metabolizing enzymes in the liver at therapeutic doses. These data contribute to the understanding of the pharmacological actions and metabolic fate of renzapride in vivo." @default.
• W56677962 created "2016-06-24" @default.
• W56677962 creator A5001031252 @default.
• W56677962 creator A5058806819 @default.
• W56677962 date "2008-01-01" @default.
• W56677962 modified "2023-10-12" @default.
• W56677962 title "Pharmacology and Metabolism of Renzapride" @default.
• W56677962 cites W1580341418 @default.
• W56677962 cites W1583060067 @default.
• W56677962 cites W1598676150 @default.
• W56677962 cites W1966092598 @default.
• W56677962 cites W1977439893 @default.
• W56677962 cites W1978850926 @default.
• W56677962 cites W1994781929 @default.
• W56677962 cites W1995641341 @default.
• W56677962 cites W1996675005 @default.
• W56677962 cites W1997018720 @default.
• W56677962 cites W1997670741 @default.
• W56677962 cites W2000535235 @default.
• W56677962 cites W2001566515 @default.
• W56677962 cites W2004164058 @default.
• W56677962 cites W2010575616 @default.
• W56677962 cites W2012492954 @default.
• W56677962 cites W2014106658 @default.
• W56677962 cites W2015634759 @default.
• W56677962 cites W2017549779 @default.
• W56677962 cites W2022788156 @default.
• W56677962 cites W2024952531 @default.
• W56677962 cites W2026395566 @default.
• W56677962 cites W2028569155 @default.
• W56677962 cites W2028880824 @default.
• W56677962 cites W2033603525 @default.
• W56677962 cites W2034075303 @default.
• W56677962 cites W2037505307 @default.
• W56677962 cites W2037676171 @default.
• W56677962 cites W2040777203 @default.
• W56677962 cites W2043972017 @default.
• W56677962 cites W2046746227 @default.
• W56677962 cites W2047499026 @default.
• W56677962 cites W2048437966 @default.
• W56677962 cites W2053074524 @default.
• W56677962 cites W2054527164 @default.
• W56677962 cites W2055882507 @default.
• W56677962 cites W2056761692 @default.
• W56677962 cites W2058424007 @default.
• W56677962 cites W2059036933 @default.
• W56677962 cites W2059230444 @default.
• W56677962 cites W2063899722 @default.
• W56677962 cites W2065113227 @default.
• W56677962 cites W2065241932 @default.
• W56677962 cites W2065655176 @default.
• W56677962 cites W2072827946 @default.
• W56677962 cites W2074631079 @default.
• W56677962 cites W2075270407 @default.
• W56677962 cites W2075704954 @default.
• W56677962 cites W2076826596 @default.
• W56677962 cites W2079204641 @default.
• W56677962 cites W2081378538 @default.
• W56677962 cites W2084177228 @default.
• W56677962 cites W2085547042 @default.
• W56677962 cites W2087688448 @default.
• W56677962 cites W2089971222 @default.
• W56677962 cites W2089996322 @default.
• W56677962 cites W2090842596 @default.
• W56677962 cites W2094089660 @default.
• W56677962 cites W2094580786 @default.
• W56677962 cites W2115667066 @default.
• W56677962 cites W2122766772 @default.
• W56677962 cites W2130837605 @default.
• W56677962 cites W2131713441 @default.
• W56677962 cites W2132854576 @default.
• W56677962 cites W2139973675 @default.
• W56677962 cites W2161618882 @default.
• W56677962 cites W2163161835 @default.
• W56677962 cites W2166217068 @default.
• W56677962 cites W2209337032 @default.
• W56677962 cites W3188280133 @default.
• W56677962 cites W3189231529 @default.
• W56677962 doi "https://doi.org/10.2165/00126839-200809010-00004" @default.
• W56677962 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7044400" @default.
• W56677962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18095752" @default.
• W56677962 hasPublicationYear "2008" @default.
• W56677962 type Work @default.
• W56677962 sameAs 56677962 @default.
• W56677962 citedByCount "14" @default.
• W56677962 countsByYear W566779622012 @default.
• W56677962 countsByYear W566779622013 @default.
• W56677962 countsByYear W566779622014 @default.
• W56677962 countsByYear W566779622016 @default.
• W56677962 countsByYear W566779622017 @default.
• W56677962 countsByYear W566779622022 @default.
• W56677962 crossrefType "journal-article" @default.
• W56677962 hasAuthorship W56677962A5001031252 @default.
• W56677962 hasAuthorship W56677962A5058806819 @default.
• W56677962 hasBestOaLocation W566779622 @default.
• W56677962 hasConcept C153911025 @default.
• W56677962 hasConcept C170493617 @default.
• W56677962 hasConcept C2778938600 @default.

• next